Facioscapulohumeral Muscular Dystrophy 1
9
2
3
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
11.1%
1 terminated out of 9 trials
75.0%
-11.5% vs benchmark
11%
1 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (9)
Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
BetterLife FSHD: A Patient-driven Health and Research Platform
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
Ultrasound Detection of Early Facial Muscle Changes in FSHD: Thickness and Echo Intensity Findings
Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension
Study to Evaluate the Efficacy and Safety of Satralizumab in FSHD1
Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal Cohort
Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders